Linked Life Data

20670085

Source:http://linkedlifedata.com/resource/pubmed/id/20670085

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20670085rdf:typepubmed:Citationlld:pubmed
pubmed-article:20670085lifeskim:mentionsumls-concept:C0206698lld:lifeskim
pubmed-article:20670085lifeskim:mentionsumls-concept:C0178602lld:lifeskim
pubmed-article:20670085lifeskim:mentionsumls-concept:C0069717lld:lifeskim
pubmed-article:20670085lifeskim:mentionsumls-concept:C0671970lld:lifeskim
pubmed-article:20670085lifeskim:mentionsumls-concept:C0045093lld:lifeskim
pubmed-article:20670085lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:20670085lifeskim:mentionsumls-concept:C1521828lld:lifeskim
pubmed-article:20670085lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:20670085lifeskim:mentionsumls-concept:C0585332lld:lifeskim
pubmed-article:20670085lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:20670085pubmed:issue3lld:pubmed
pubmed-article:20670085pubmed:dateCreated2011-3-14lld:pubmed
pubmed-article:20670085pubmed:abstractTextGemcitabine based regimens have been widely used in patients with advanced cholangiocarcinoma (CC), but no standard therapy exists. In this study we aimed to find the maximally tolerated dose (MTD) of a two-week schedule of fixed dose rate (FDR) gemcitabine (G), oxaliplatin (O) and capecitabine (C), and evaluate the safety and efficacy of this regimen in patients with advanced cholangiocarcinoma (CC).lld:pubmed
pubmed-article:20670085pubmed:languageenglld:pubmed
pubmed-article:20670085pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20670085pubmed:citationSubsetIMlld:pubmed
pubmed-article:20670085pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20670085pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20670085pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20670085pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20670085pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20670085pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20670085pubmed:statusMEDLINElld:pubmed
pubmed-article:20670085pubmed:monthAprlld:pubmed
pubmed-article:20670085pubmed:issn1651-226Xlld:pubmed
pubmed-article:20670085pubmed:authorpubmed-author:JakobsenAnder...lld:pubmed
pubmed-article:20670085pubmed:authorpubmed-author:LassenUlrikUlld:pubmed
pubmed-article:20670085pubmed:authorpubmed-author:SorensenMorte...lld:pubmed
pubmed-article:20670085pubmed:authorpubmed-author:JensenLars...lld:pubmed
pubmed-article:20670085pubmed:authorpubmed-author:RohrbergKrist...lld:pubmed
pubmed-article:20670085pubmed:authorpubmed-author:UjmajuridzeZa...lld:pubmed
pubmed-article:20670085pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20670085pubmed:volume50lld:pubmed
pubmed-article:20670085pubmed:ownerNLMlld:pubmed
pubmed-article:20670085pubmed:authorsCompleteYlld:pubmed
pubmed-article:20670085pubmed:pagination448-54lld:pubmed
pubmed-article:20670085pubmed:meshHeadingpubmed-meshheading:20670085...lld:pubmed
pubmed-article:20670085pubmed:meshHeadingpubmed-meshheading:20670085...lld:pubmed
pubmed-article:20670085pubmed:meshHeadingpubmed-meshheading:20670085...lld:pubmed
pubmed-article:20670085pubmed:meshHeadingpubmed-meshheading:20670085...lld:pubmed
pubmed-article:20670085pubmed:meshHeadingpubmed-meshheading:20670085...lld:pubmed
pubmed-article:20670085pubmed:meshHeadingpubmed-meshheading:20670085...lld:pubmed
pubmed-article:20670085pubmed:meshHeadingpubmed-meshheading:20670085...lld:pubmed
pubmed-article:20670085pubmed:meshHeadingpubmed-meshheading:20670085...lld:pubmed
pubmed-article:20670085pubmed:meshHeadingpubmed-meshheading:20670085...lld:pubmed
pubmed-article:20670085pubmed:meshHeadingpubmed-meshheading:20670085...lld:pubmed
pubmed-article:20670085pubmed:meshHeadingpubmed-meshheading:20670085...lld:pubmed
pubmed-article:20670085pubmed:meshHeadingpubmed-meshheading:20670085...lld:pubmed
pubmed-article:20670085pubmed:meshHeadingpubmed-meshheading:20670085...lld:pubmed
pubmed-article:20670085pubmed:meshHeadingpubmed-meshheading:20670085...lld:pubmed
pubmed-article:20670085pubmed:meshHeadingpubmed-meshheading:20670085...lld:pubmed
pubmed-article:20670085pubmed:meshHeadingpubmed-meshheading:20670085...lld:pubmed
pubmed-article:20670085pubmed:meshHeadingpubmed-meshheading:20670085...lld:pubmed
pubmed-article:20670085pubmed:meshHeadingpubmed-meshheading:20670085...lld:pubmed
pubmed-article:20670085pubmed:year2011lld:pubmed
pubmed-article:20670085pubmed:articleTitleA Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas.lld:pubmed
pubmed-article:20670085pubmed:affiliationDepartment of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen, Denmark. ulrik.lassen@rh.regionh.dklld:pubmed
pubmed-article:20670085pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20670085pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:20670085pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:20670085pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
pubmed-article:20670085pubmed:publicationTypeClinical Trial, Phase Illd:pubmed